Since 2005, the DNDi office in the Democratic Republic of Congo (DRC) has provided essential logistical and financial support for the nifurtimox-eflornithine clinical trial (NECT), the fexinidazole trials, and the HAT Platform.



DNDi in Democratic Republic of Congo

Avenue Milambo, n°4
Quartier Socimat
Commune de la Gombe
Kinshasa
Democratic Republic of the Congo

Tel: +243 81 659 79 95

 


  • Top-line results from the fexinidazole Phase III/IV study enable DNDi and Sanofi to pursue plans to submit for regulatory approval with the EMA in 2017.
  • Phase II/III study starts in seven sites in DRC to test SCYX-7158 as a single-dose treatment in 350 patients with stage 2 HAT.